glp-1 discontinuation Many adults stop therapy within a year with low restart rates, analysis finds Most Patients Discontinue GLP-1 Drugs

Semaglutide is a GLP-1 receptor agonist, a peptide-based medication

These medications, when prescribed by qualified professionals, provide a tool for individuals to regain control over their health and confidence

Demand is projected to increase from USD 220.7 million in 2026 to USD 1,150.0 million by 2036

29 In fact, participating providers are encouraged to purchase high-cost prescription drugs to receive more substantial discounts under 340B that effectively pad providers bottom lines

Moore, J., Wood, J

Neither medication requires functioning pancreatic beta cells to work, making them suitable for advanced type 2 diabetes